JAK1/2通路抑制通过降低TRIB1、MUC1、CD44、CXCL12和CXCR4表达抑制M2极化并克服骨髓瘤对来那度胺的耐药
本研究探讨JAK1/2抑制剂芦可替尼对多发性骨髓瘤(MM)中M2巨噬细胞极化及来那度胺耐药的影响。结果显示,MM进展期患者骨髓M2细胞增多而M1减少,TRIB1表达升高;芦可替尼在体外及人MM异种移植模型中显著抑制M2极化和TRIB1表达,并下调CXCL12、CXCR4、MUC1和CD44,这些基因过表达与来那度胺耐药相关。结果提示JAK抑制剂联合来那度胺治疗MM的合理性。
要点
- MM进展期患者骨髓M2细胞增多、M1减少,且TRIB1表达升高
- 芦可替尼在体外和体内均抑制M2极化和TRIB1表达
- 芦可替尼下调CXCL12、CXCR4、MUC1和CD44,克服来那度胺耐药
核心结论
- JAK1/2通路抑制可抑制M2极化并下调耐药相关基因,为JAK抑制剂联合来那度胺治疗MM提供依据。
研究设计与样本
- 研究比较MM患者进展期与完全缓解期骨髓中M1/M2细胞及TRIB1表达,并在体外及人MM异种移植SCID小鼠模型中评估芦可替尼作用。
主要发现
- MM进展期患者骨髓M2细胞较完全缓解期增多,M1细胞减少,TRIB1基因表达升高。
- 芦可替尼在体外和体内均显著减少MM中M2极化和TRIB1基因表达。
- 芦可替尼下调MM细胞及与MM肿瘤细胞共培养的单核细胞中CXCL12、CXCR4、MUC1和CD44的表达。
临床怎么用
- JAK抑制剂(包括在MM骨髓微环境中)联合来那度胺可能成为MM治疗策略,尤其针对来那度胺耐药患者。
局限性
- 研究主要基于体外实验和异种移植模型,尚需临床研究验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Monocytes polarize into pro-inflammatory macrophage-1 (M1) or alternative macrophage-2 (M2) states with distinct phenotypes and physiological functions. M2 cells promote tumour growth and metastasis whereas M1 macrophages show anti-tumour effects. We found that M2 cells were increased whereas M1 cells were decreased in bone marrow (BM) from multiple myeloma (MM) patients with progressive disease (PD) compared to those in complete remission (CR). Gene expression of Tribbles homolog 1 (TRIB1) protein kinase, an inducer of M2 polarization, was increased in BM from MM patients with PD compared to those in CR. Ruxolitinib (RUX) is an inhibitor of the Janus kinase family of protein tyrosine kinases (JAKs) and is effective for treating patients with myeloproliferative disorders. RUX markedly reduces both M2 polarization and TRIB1 gene expression in MM both in vitro and in vivo in human MM xenografts in severe combined immunodeficient mice. RUX also downregulates the expression of CXCL12, CXCR4, MUC1, and CD44 in MM cells and monocytes co-cultured with MM tumour cells; overexpression of these genes is associated with resistance of MM cells to the immunomodulatory agent lenalidomide. These results provide the rationale for evaluation of JAK inhibitors, including MM BM in combination with lenalidomide, for the treatment of MM patients.
引用
- Chen H, Li M, Sanchez E, et al. JAK1/2 pathway inhibition suppresses M2 polarization and overcomes resistance of myeloma to lenalidomide by reducing TRIB1, MUC1, CD44, CXCL12, and CXCR4 expression. Br J Haematol. 2019. PMID: 31423579. doi:10.1111/bjh.16158
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。